148 related articles for article (PubMed ID: 29847952)
21. NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy.
Li G; Xu Y; Kong X; Gu L; Qin Y; Wu L
Chem Commun (Camb); 2023 May; 59(42):6343-6346. PubMed ID: 37132604
[TBL] [Abstract][Full Text] [Related]
22. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy.
Pei Q; Lu S; Zhou J; Jiang B; Li C; Xie Z; Jing X
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59708-59719. PubMed ID: 34879654
[TBL] [Abstract][Full Text] [Related]
23. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
[TBL] [Abstract][Full Text] [Related]
24. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.
Beall HD; Hudnott AR; Winski S; Siegel D; Swann E; Ross D; Moody CJ
Bioorg Med Chem Lett; 1998 Mar; 8(5):545-8. PubMed ID: 9871615
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
Beall HD; Winski SI
Front Biosci; 2000 Jul; 5():D639-48. PubMed ID: 10877993
[TBL] [Abstract][Full Text] [Related]
26. Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2.
Swann E; Barraja P; Oberlander AM; Gardipee WT; Hudnott AR; Beall HD; Moody CJ
J Med Chem; 2001 Sep; 44(20):3311-9. PubMed ID: 11563930
[TBL] [Abstract][Full Text] [Related]
27. Detection and cellular imaging of human cancer enzyme using a turn-on, wavelength-shiftable, self-immolative profluorophore.
Hettiarachchi SU; Prasai B; McCarley RL
J Am Chem Soc; 2014 May; 136(21):7575-8. PubMed ID: 24813575
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
[TBL] [Abstract][Full Text] [Related]
29. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
30. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
31. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
[TBL] [Abstract][Full Text] [Related]
32. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
[TBL] [Abstract][Full Text] [Related]
34. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
35. Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Shin WS; Han J; Verwilst P; Kumar R; Kim JH; Kim JS
Bioconjug Chem; 2016 May; 27(5):1419-26. PubMed ID: 27135737
[TBL] [Abstract][Full Text] [Related]
36. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.
Gaikwad NW; Rogan EG; Cavalieri EL
Free Radic Biol Med; 2007 Nov; 43(9):1289-98. PubMed ID: 17893042
[TBL] [Abstract][Full Text] [Related]
37. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
Fagan V; Bonham S; Carty MP; Saenz-Méndez P; Eriksson LA; Aldabbagh F
Bioorg Med Chem; 2012 May; 20(10):3223-32. PubMed ID: 22522008
[TBL] [Abstract][Full Text] [Related]
38. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
Schäfer A; Burstein ES; Olsson R
Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
[TBL] [Abstract][Full Text] [Related]
39. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
[TBL] [Abstract][Full Text] [Related]
40. Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
Kadela-Tomanek M; Jastrzębska M; Pawełczak B; Bębenek E; Chrobak E; Latocha M; Książek M; Kusz J; Boryczka S
Eur J Med Chem; 2017 Jan; 126():969-982. PubMed ID: 28006669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
